PTA-Adhoc: Dr. Hönle AG: Hönle achieves an operating result of € 7.2 million in the 9-month period
Public disclosure of inside information according to article 17 MAR
Gilching (pta042/29.07.2022/14:20) - Earnings in the third quarter were worse than planned. The situation on procurement markets and the increase in energy prices burden on quarterly earnings heavily. In addition, one-time effects affected the result. These are largely related to the personnel changes implemented at the management level of Dr. Hönle AG.
According to preliminary figures, the Hönle Group's sales in the nine-month period increased by 12.0% to T€ 95,141 compared to the same period of the previous year. At T€ 7,214, the operating result (EBIT) was 0.7% above the previous year's level. This corresponds to an EBIT margin of 7.1% after 8.2% in the previous year. Earnings before taxes (EBT) were T€ 6,138 (PY: T€ 6,395). After income taxes, the consolidated result was T€ 4,736, which corresponds to a decrease of 2.3%. Earnings per share fell slightly from €0.79 to €0.77.
For the fourth quarter of the current financial year, the Executive Board does not expect any relaxation on the procurement markets and, in addition, a further increase in energy prices. Energy prices are significantly influenced by the Russia-Ukraine war and security of supply through the Nord Stream 1 gas pipeline.
This development has a strong impact on the profitability of Raesch Quarz (Germany) GmbH in particular, therefore the Board of Management expects a significant burden on earnings. The situation on the procurement markets will probably lead to a temporary burden on the gross profit margins in the fourth quarter and to orders having to be postponed.
In addition, the Hönle Group expects larger orders in the adhesives segment, which are likely to be postponed to the next financial year.
As already communicated in the report dated July 22, 2022, the Management Board expects sales for the Hönle Group of € 125 to 130 million (PY: € 115 million) and an operating result (EBIT) of between 9 and € 11 million (PY: € 0.3 million) in the 2021/2022 financial year.
The high order backlog of the Hönle Group and a large number of ongoing customer projects represent a good starting point for the new financial year. The burden on margins in the current financial year will probably be compensated in the financial year 2022/2023 due to sales price adjustments that have already taken place or are planned.
If the general economic conditions remain the same, increasing sales and earnings are therefore expected in the 2022/2023 financial year.
As planned, the 2021/2022 9-month statement will be published on August 5, 2022 and will then be available on the Internet at https://www.hoenle.com/investor-relation/financial-information.
Dr. Hönle AG is a listed technology company headquartered in Gilching, Germany. With its nearly 700 employees, the Hönle Group develops innovative solutions for a wide variety of industrial manufacturing processes. One focus of its activities is the development and sale of industrial adhesives and casting compounds. Moreover, the company manufactures equipment for ink and paint drying, adhesives and plastic curing as well as for air, water and surface disinfection and sunlight simulation. In addition, the corporate group produces UV lamps for disinfection and drying processes, among others, and manufactures tubes and semi-finished products made of quartz glass for use in various branches of industry. The Hönle Group supplies technology and world market leaders worldwide and is represented by its own entities and partner companies in more than 20 countries.
emitter: Dr. Hönle AG
address: Nicolaus-Otto-Str. 2, 82205 Gilching
contact person: Peter Weinert
phone: +49 8105 2083 173
ISIN(s): DE0005157101 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate